Black Diamond Therapeutics BDTX
NASDAQ BDTX
$1.88 -0.20 (-9.62%)
At close: Oct 23, 2026 · 4:00 PM EDT

Black Diamond Therapeutics (BDTX) Return on Sales [ROS] (2025)

Updated

Black Diamond Therapeutics' Return on Sales [ROS] was 17.89% in Q4 2025, up 0.95 percentage points from the prior quarter.

Analysis

Black Diamond Therapeutics (BDTX) Return on Sales [ROS] (2025) Analysis & Trends

From Q1 2025 onward, Black Diamond Therapeutics has reported Return on Sales [ROS] for 4 quarters.

  • Quarterly Return on Sales [ROS] has moved between 6.72% (Q2 2025) and 77.90% (Q1 2025) over five years.
  • Per Business Quant data, BDTX's Return on Sales [ROS] in the three quarters before Q4 2025 was 16.94% (Q3 2025), 6.72% (Q2 2025) and 77.90% (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn 24.35%
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn 37.86%
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn -3.52%
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn 32.97%
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn 20.57%
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn 34.95%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -133.21%
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn 28.37%
10 Black Diamond Therapeutics 108.71 Mn -384.21 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 17.89%
Sep 30, 2025 16.94%
Jun 30, 2025 6.72%
Mar 31, 2025 77.90%
API Access

Black Diamond Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=BDTX&period=max&api_key=YOUR_API_KEY